Published in Blood Weekly, July 6th, 2006
The results of these studies were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.
The seven studies investigate a variety of uses for Vidaza - including alternative dosing schedules, and combination use with approved and/or investigational therapies, such as thalidomide, carboplatin and the histone deacetylase (HDAC) inhibitor valproic acid (VPA). Two of these studies explore the feasibility of the emerging...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.